<DOC>
	<DOCNO>NCT00540618</DOCNO>
	<brief_summary>To compare disease activity , measure PASI score , three MEDI-507 dosing ( injection ) regimens vs. placebo .</brief_summary>
	<brief_title>A Phase II Study MEDI-507 , Administered Injection Adults With Psoriasis</brief_title>
	<detailed_description>The primary objective study compare disease activity , measure PASI score , three MEDI-507 dose regimen ( 5 mg 12 week , 5 mg 6 week , 7 mg 4 week ) versus placebo administer weekly SC injection .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Plaque psoriasis involve least 10 % body surface area Age 18 65 year time first dose study drug Both males female eligible . However , sexually active female , unless surgically sterile least 1 year postmenopausal , must use effective method avoid pregnancy ( include oral implanted contraceptive , IUD , female condom , diaphragm spermicide , cervical cap , abstinence , use condom sexual partner sterile sexual partner ) 30 day prior first dose study drug must agree continue Currently receive therapy psoriasis except emollient ( certain overthecounter product may allow prior approval sponsor ) Written informed consent obtain patient Ability complete followup period 167 day require protocol Pustular , guttate , erythrodermic psoriasis predominant disease type PASI score &lt; 8 At screening ( must within 21 day study entry ) following : lymphocyte count 1,200 cells/mm3 , WBC 4,000 cells/mm3 , hematocrit 32 % , platelets 110,000 cells/mm3 , creatinine , AST , ALT 1.5 time upper limit normal At screen ( must within 21 day study entry ) clinical evidence HIV , hepatitis B , hepatitis C active hepatitis A infection Pregnancy ( must negative serum pregnancy test within 21 day prior first dose study drug , urine pregnancy test must negative Study Day 0 study entry ) History cancer ( except excision basal cell carcinoma ) Any document immunodeficiency A history prior administration monoclonal antibody relate protein Receipt systemic retinoids , corticosteroid , cyclosporin A , methotrexate , phototherapy coal tar treatment past 4 week Use topical therapy ( except emollient ) psoriasis past 2 week ( certain overthecounter product may allow prior approval sponsor ) Receipt investigational drug therapy within 6 week first dose study drug protocol ( use license agent indication list package insert permit ) Current plan participation research protocol investigational agent therapy may administer Nursing mother Acute illness include infection 15 . Clinical manifestation significant end organ dysfunction failure may compromise safety volunteer study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>